---
figid: PMC10150365__jm3c00156_0002
figtitle: HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from
  a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other
  Malignancies
organisms:
- Homo sapiens
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC10150365
filename: jm3c00156_0002.jpg
figlink: /pmc/articles/PMC10150365/figure/fig1/
number: F1
caption: Complex cellular structure–activity relationships (SARs) of the bisamide
  chemotype and poor rat-free exposure from an oral dose of the lead compound 1.
papertitle: HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed
  from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer
  and Other Malignancies.
reftext: A. Elisa Pasqua, et al. J Med Chem. 2023 Apr 27;66(8):5907-5936.
year: '2023'
doi: 10.1021/acs.jmedchem.3c00156
journal_title: Journal of Medicinal Chemistry
journal_nlm_ta: J Med Chem
publisher_name: American Chemical Society
keywords: ''
automl_pathway: 0.7860014
figid_alias: PMC10150365__F1
figtype: Figure
redirect_from: /figures/PMC10150365__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10150365__jm3c00156_0002.html
  '@type': Dataset
  description: Complex cellular structure–activity relationships (SARs) of the bisamide
    chemotype and poor rat-free exposure from an oral dose of the lead compound 1.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - SARDH
  - SRL
  - NR1I2
  - GPR162
  - F11
  - ZNF160
  - br
  - Pen
  - alphaTub85E
  - Prosalpha2
  - nAChRalpha2
  - Rst(2)At
  - Tgi
---
